Literature DB >> 23336959

Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study.

Gregory Y H Lip1, Hung-Ju Lin, Hsiu-Ching Hsu, Ta-Chen Su, Ming-Fong Chen, Yuan-Teh Lee, Kuo-Liong Chien.   

Abstract

BACKGROUND: The HAS-BLED score is a validated bleeding risk model for predicting major bleeding events in anticoagulated individuals with atrial fibrillation (AF). It remains uncertain whether the HAS-BLED score could identify non-AF individuals at risk of developing intracranial haemorrhage (ICH), which is the most intractable and devastating major bleeding complication.
METHODS: We assessed the predictive value of a modified HAS-BLED and other bleeding risk scoring models to predict the risk for ICH in the Chin-Shan Community Cohort, which followed 1899 women and 1703 men, aged >35 years, for a median of 15.9 years. ICH events (including haemorrhagic strokes) were ascertained according to questionnaires and the national register database.
RESULTS: Of 3524 individuals without baseline AF, 54 ICH events occurred during follow-up. The risk for ICH was raised with increasing HAS-BLED scores, and was significantly associated with uncontrolled hypertension and older age (Odds Ratios [95% confidence interval (CI)], 4.2[2.3-7.6] and 1.9[1.1-3.4], respectively). Among the five bleeding risk scoring schemes tested, HAS-BLED had highest general discrimination performance (c-statistic [95% CI], 0.72 [0.67-0.78]), and better ability to discriminate between those who were at risk for ICH and who were not (NRI, net reclassification improvement, all p<0.05, compared to other four scoring schemes).
CONCLUSION: The HAS-BLED score had the highest general discrimination performance and best ability to discriminate risk for ICH. This score may be of clinical use in predicting the risk for occurrence of ICH among non-AF individuals.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bleeding risk score; Intracranial haemorrhage; Prediction

Mesh:

Year:  2013        PMID: 23336959     DOI: 10.1016/j.ijcard.2012.12.076

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Separate prediction of intracerebral hemorrhage and ischemic stroke.

Authors:  Bart S Ferket; Bob J H van Kempen; Renske G Wieberdink; Ewout W Steyerberg; Peter J Koudstaal; Albert Hofman; Eyal Shahar; Rebecca F Gottesman; Wayne Rosamond; Jorge R Kizer; Richard A Kronmal; Bruce M Psaty; W T Longstreth; Thomas Mosley; Aaron R Folsom; M G Myriam Hunink; M Arfan Ikram
Journal:  Neurology       Date:  2014-04-23       Impact factor: 9.910

2.  Validation Of The HAS-BLED Tool In Atrial Fibrillation Patients Receiving Rivaroxaban.

Authors:  E W Gorman; D Perkel; D Dennis; J Yates; R E Heidel; D Wortham
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 3.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

4.  The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.

Authors:  Judith Kooiman; Nadja van Hagen; Antonio Iglesias Del Sol; Erwin V Planken; Gregory Y H Lip; Felix J M van der Meer; Suzanne C Cannegieter; Frederikus A Klok; Menno V Huisman
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

5.  Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project.

Authors:  Yu-Tao Guo; Ye Zhang; Xiang-Min Shi; Zhao-Liang Shan; Chun-Jiang Wang; Yu-Tang Wang; Yun-Dai Chen; Gregory Y H Lip
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

6.  Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication.

Authors:  Diana M Rydberg; Marie Linder; Rickard E Malmström; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2020-03-28       Impact factor: 2.953

7.  Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits.

Authors:  Bo Yu; Victor Perez Gutierrez; Alex Carlos; Gregory Hoge; Anjana Pillai; J Daniel Kelly; Vidya Menon
Journal:  Biomark Res       Date:  2021-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.